Literature DB >> 10681606

Clinical, histological and immunopathological features of 58 patients with subacute cutaneous lupus erythematosus. A review by the Italian group of immunodermatology.

A Parodi1, M Caproni, C Cardinali, E Bernacchi, A Fuligni, G De Panfilis, C Zane, M Papini, F C Veller, M Vaccaro, P Fabbri.   

Abstract

BACKGROUND: Subacute cutaneous lupus erythematosus (SCLE) is a distinct subset of cutaneous lupus erythematosus clinically characterized by psoriasiform and/or annular lesions and by a mild or absent systemic involvement.
OBJECTIVE: The Italian Group of Immunodermatology of the Italian Society of Dermatology and Venereology reviewed the cases of SCLE seen in 10 years (1987-1996). PATIENTS: Forty-six women and 12 men have been retrospectively studied, 42% had annular lesions, 39% psoriasiform ones and 16% both.
RESULTS: Lesions were mainly localized on the neck and face and relapsed in spring and autumn. Seventeen patients had 4 or more American College of Rheumatology criteria and could be classified as having systemic lupus erythematosus. The most frequent histopathological alterations were epidermal atrophy, hydropic degeneration of the basal layer and perivascular lymphocytic infiltrate. Deposits of immunoglobulins and C3 at the dermo-epidermal junction on the clinically involved skin were present in 86% of the patients. Dust-like particles in the epidermis were only found in 3% of cases. Anti-Ro/SSA antibodies were found in 71% of the cases and anti-dsDNA only in 5% of cases.
CONCLUSIONS: SCLE is a particular subset of cutaneous lupus erythematosus with peculiar clinical and immunopathological features. Copyright (R) 2000 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10681606     DOI: 10.1159/000018307

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  9 in total

1.  [Cutaneous lupus erythematosus. Part 1: clinical manifestations and classification].

Authors:  A Kuhn; K Gensch; S Ständer; G Bonsmann
Journal:  Hautarzt       Date:  2006-03       Impact factor: 0.751

2.  Intravenous immunoglobulin in the treatment of resistant subacute cutaneous lupus erythematosus: a possible alternative.

Authors:  Christos E Lampropoulos; Graham R V Hughes; David P D' Cruz
Journal:  Clin Rheumatol       Date:  2006-05-03       Impact factor: 2.980

3.  [Drug-induced subacute cutaneous lupus erythematosus: repeated occurrence following treatment with terbinafine].

Authors:  G Wagner; M M Sachse
Journal:  Hautarzt       Date:  2014-06       Impact factor: 0.751

4.  James Neil Gilliam, MD-the career arc of a patient-oriented translational clinical investigation changemaker in rheumatologic skin disease.

Authors:  Richard D Sontheimer
Journal:  Ann Transl Med       Date:  2018-06

Review 5.  Cutaneous lupus erythematosus: diagnosis and treatment.

Authors:  L G Okon; V P Werth
Journal:  Best Pract Res Clin Rheumatol       Date:  2013-06       Impact factor: 4.098

6.  Clinical characteristics of cutaneous lupus erythematosus.

Authors:  Justyna Szczęch; Maja Rutka; Dominik Samotij; Agnieszka Zalewska; Adam Reich
Journal:  Postepy Dermatol Alergol       Date:  2016-02-29       Impact factor: 1.837

7.  Immunohistochemical study of annular erythema appearing in a patient with sub-acute cutaneous lupus erythematosus.

Authors:  Kaori Shima; Takashi Nomura; Satoru Yonekura; Yuki Honda Keith; Toshiaki Kogame; Kosaku Murakami; Kenji Kabashima
Journal:  Skin Health Dis       Date:  2022-06-15

Review 8.  Autoantibodies and their Judicious Use in Pediatric Rheumatology Practice.

Authors:  Biman Saikia; Amit Rawat; Pandiarajan Vignesh
Journal:  Indian J Pediatr       Date:  2015-12-03       Impact factor: 5.319

9.  A case of subacute cutaneous lupus erythematosus in a patient with mixed connective tissue disease: successful treatment with plasmapheresis and rituximab.

Authors:  M Fantò; S Salemi; F Socciarelli; A Bartolazzi; G A Natale; I Casorelli; A Pavan; S Vaglio; R Di Rosa; R D'Amelio
Journal:  Case Rep Rheumatol       Date:  2013-07-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.